Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2021.07.08
DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive A ...
PDF (330 KB)
2021.06.14
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 ...
PDF (331 KB)
2021.06.11
Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell ...
PDF (262 KB)
2021.06.04
Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanism ...
PDF (206 KB)
2021.05.19
Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 202 ...
PDF (303 KB)
2021.05.08
Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and D ...
PDF (236 KB)
2021.05.06
Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the ...
PDF (177 KB)
2021.04.07
Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myelo ...
PDF (176 KB)
2021.04.06
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Col ...
PDF (361 KB)
2021.03.29
DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Sma ...
PDF (298 KB)
Showing 1 - 10 of 34 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...